A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Bowles, D W
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. [electronic resource] - British journal of cancer Sep 2013 - 1085-92 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1532-1827
10.1038/bjc.2013.474 doi
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers, Tumor--blood
Disease-Free Survival
Docetaxel
Female
Gonanes--adverse effects
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy
Phosphoinositide-3 Kinase Inhibitors
Taxoids--adverse effects
Treatment Outcome
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. [electronic resource] - British journal of cancer Sep 2013 - 1085-92 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1532-1827
10.1038/bjc.2013.474 doi
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers, Tumor--blood
Disease-Free Survival
Docetaxel
Female
Gonanes--adverse effects
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy
Phosphoinositide-3 Kinase Inhibitors
Taxoids--adverse effects
Treatment Outcome